Physician profile
Boris Schwartz
NPI 1679601603
$1,081.03
in general payments reported to CMS, 2019-2025
14 companies · $768 in 2025
The $768 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.69 · 2022: $72.44 · 2023: $52.42 · 2024: $161 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $613 · Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $612.50 |
| Food and Beverage | $369.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $682.69 | 2025 | Roxybond |
| Daiichi Sankyo INC. | $77.15 | 2024-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $71.80 | 2022-2023 | |
| Boston Scientific Corporation | $45.16 | 2022-2024 | |
| Abbott Laboratories | $33.15 | 2023-2025 | Proclaim |
| Eisai INC. | $24.55 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $23.42 | 2024 | Uptravi, Opsumit |
| Ethicon INC. | $22.37 | 2024 | Monarch Platform |
| Madrigal Pharmaceuticals | $21.69 | 2025 | Rezdiffra |
| Phadia US INC. | $19.41 | 2023 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $16.67 | 2025 | Rexulti |
| Abiomed | $16.28 | 2024 | Impella |
| Medtronic, INC. | $14.31 | 2021 | |
| Bardy Diagnostics, INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.